Moreover, the Oslo-2 mAb did not bind to the HER2+ lung cancer cell line A549, or to HER2 negative prostate cancer, pancreatic cancer, lymphoma and leukemia cell lines (Figure 2). This evidence concerns the gene ERBB2 and lymphoma.